ArticleIn vivo (Athens, Greece)
Association Between Dipeptidyl Peptidase-4 Inhibitor Use and Acute Kidney Injury in Patients With Diabetes Mellitus: A Disproportionality Analysis Based on the FAERS.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nutrient metabolic heterogeneity across renal stages in patients with type 2 diabetes mellitus and diabetic kidney disease.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimAlthough dipeptidyl peptidase-4 inhibitors (DPP4is) are widely used in the treatment of diabetes, a known risk factor for renal function decline, the potential association between DPP4i use and acute kidney injury (AKI) remains controversial. This study aimed to evaluate the association between DPP4i and AKI while considering the concomitant use of inducers of AKI in patients with diabetes. PATIENTS AND
methodsData from the US Food and Drug Administration Adverse Event Reporting System were analyzed, focusing on seven DPP4is in daily use, namely alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin, and vildagliptin. Disproportionality analysis was performed to determine the association between DPP4i use and AKI using reporting odds ratios and information components, stratified by age groups, in the presence or absence of 10 types of AKI inducer used concomitantly.
resultsOf 215,051 reports, a positive association between DPP4i and AKI was found for linagliptin, sitagliptin, and vildagliptin in the overall analysis. Age-stratified analysis revealed associations between the DPP4is linagliptin, saxagliptin, sitagliptin and vildagliptin and AKI in the middle-aged group of patients, whereas only sitagliptin and vildagliptin were associated with AKI in the elderly group. Exclusion of concomitant renin-angiotensin-aldosterone system inhibitors, diuretics, or non-steroidal anti-inflammatory drugs altered signal detection for certain DPP4is, with these changes varying by age group.
conclusionThis study suggests that some DPP4is, including linagliptin, sitagliptin and vildagliptin, are associated with AKI, even without concomitant use of an AKI inducer. Given the widespread use of DPP4is and the severity of AKI, clinicians should be sufficiently informed about their potential relationship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.